Want to see JP:4506 full AI Analyst Report?
4506 Stock Chart & Stats
¥1854.50
¥4.00(0.72%)
At close: 4:00 PM EST
¥1854.50
¥4.00(0.72%)
Day’s Range― - ―
52-Week Range¥1,035.00 - ¥3,288.00
Previous CloseN/A
Volume1.08M
Average Volume (3M)5.45M
Market Cap
¥565.68B
Enterprise Value¥1.00M
Total Cash (Recent Filing)¥44.31B
Total Debt (Recent Filing)¥217.19B
Price to Earnings (P/E)4.7
Beta1.33
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)268.99
Shares Outstanding449,204,560
10 Day Avg. Volume5,265,230
30 Day Avg. Volume5,454,233
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.82
Price to Sales (P/S)1.82
P/FCF Ratio12.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,500.00Price Target Upside-19.12% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)212.31
Revenue Forecast (FY)¥541.87B
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundThe sharp profitability rebound in 2026 demonstrates the company’s ability to restore operating margins after losses, improving sustainable earnings power. Over the next 2–6 months this stronger profit base should support reinvestment into R&D and reduce near-term solvency pressure, increasing the durability of cash generation when markets or product cycles normalize.
Improved LeverageMaterial leverage improvement provides greater financial flexibility and lowers interest burden, which is durable over the medium term. A healthier capital structure enhances the firm’s ability to fund clinical programs, absorb setbacks, and pursue strategic partnerships without immediate refinancing stress, supporting stability across business cycles.
Stronger Cash GenerationSubstantially improved free cash flow and high conversion to net income indicate better cash quality and internal funding capacity. This strengthens the company’s ability to finance R&D, manufacturing, or strategic deals organically over coming quarters, reducing reliance on external capital if the improved cash profile sustains.
Bears Say
Revenue VolatilityMarked top-line swings reduce predictability of margins and cash flow, complicating investment and operational planning. Over a 2–6 month horizon this uneven revenue trajectory weakens visibility into sustainable demand, heightens risk of shortfalls versus budgeted R&D or commercialization spending, and raises execution risk tied to product mix.
Inconsistent Cash Flow HistoryHistorical swings in cash flow and past major outflows indicate the company’s cash generation is not yet stable. This inconsistency can restrict funding for drug development or force external financing in adverse periods, creating medium-term execution and refinancing risk even if 2026 improved cash flow is encouraging.
Product Lifecycle & Pricing RiskRevenue and earnings depend heavily on successful drug development, regulatory approvals, patent life, and Japan’s pricing/reimbursement system. These structural industry factors produce binary outcomes and long lead times, meaning medium-term fundamentals remain exposed to regulatory decisions and competitive/expiry-driven revenue declines.
Sumitomo Dainippon Pharma Co News
4506 FAQ
What was Sumitomo Dainippon Pharma Co Ltd’s price range in the past 12 months?
Sumitomo Dainippon Pharma Co Ltd lowest stock price was ¥1035.00 and its highest was ¥3288.00 in the past 12 months.
What is Sumitomo Dainippon Pharma Co Ltd’s market cap?
Sumitomo Dainippon Pharma Co Ltd’s market cap is ¥565.68B.
When is Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date?
Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date is Jul 31, 2026 which is in 11 days.
How were Sumitomo Dainippon Pharma Co Ltd’s earnings last quarter?
Sumitomo Dainippon Pharma Co Ltd released its earnings results on May 13, 2026. The company reported -¥2.04 earnings per share for the quarter, beating the consensus estimate of -¥15.241 by ¥13.201.
Is Sumitomo Dainippon Pharma Co Ltd overvalued?
According to Wall Street analysts Sumitomo Dainippon Pharma Co Ltd’s price is currently Overvalued.
Does Sumitomo Dainippon Pharma Co Ltd pay dividends?
Sumitomo Dainippon Pharma Co Ltd pays a Semiannually dividend of ¥7 which represents an annual dividend yield of N/A. See more information on Sumitomo Dainippon Pharma Co Ltd dividends here
What is Sumitomo Dainippon Pharma Co Ltd’s EPS estimate?
Sumitomo Dainippon Pharma Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sumitomo Dainippon Pharma Co Ltd have?
Sumitomo Dainippon Pharma Co Ltd has 449,204,560 shares outstanding.
What happened to Sumitomo Dainippon Pharma Co Ltd’s price movement after its last earnings report?
Sumitomo Dainippon Pharma Co Ltd reported an EPS of -¥2.04 in its last earnings report, beating expectations of -¥15.241. Following the earnings report the stock price went up 2.516%.
Which hedge fund is a major shareholder of Sumitomo Dainippon Pharma Co Ltd?
Currently, no hedge funds are holding shares in JP:4506
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
4506 Stock 12 Month Forecast
Average Price Target
¥1,500.00
▼(-19.12% Downside)
Technical Analysis
Eisai Co
―
Kissei Pharmaceutical Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Nippon Shinyaku Co., Ltd.
―